Previous 10 | Next 10 |
2023-10-25 10:13:59 ET More on Cybin Cybin Inc. 2023 FQ1 - Results - Earnings Call Presentation Psychedelic drug developer Cybin completes acquisition of Small Pharma Psychedelic drugs market to break $7B in 2029 led by these 3 meds Seeking Alpha’s Qua...
- New United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis - - Intellectual Property portfolio provides robust protection for most extensive deuterated DMT portfolio in the sector - - Cybin’s I...
2023-10-23 15:05:20 ET More on Cybin Cybin Inc. 2023 FQ1 - Results - Earnings Call Presentation Psychedelic drugs market to break $7B in 2029 led by these 3 meds Cybin in pact to support training in Phase 3 psychedelic trial Seeking Alpha’s Quant Ratin...
Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to ...
This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023. - Combined portfolios create the industry’s largest, most adv...
2023-10-19 10:10:00 ET October 19, 2023 (Investorideas.com Newswire) Investorideas.com ( https://www.investorideas.com ) a global investor news source covering psilocybin and psychedelic health and wellness stocks releases a special news report featuring Kaya Holdings, Inc. ( OTCQB:KA...
Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharma...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the results of its annual and special meeting of shareholders, which was h...
Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be presenting at the Neuropsychiatric Drug Development Summit, slated for Oct. 11...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...